These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19675265)

  • 1. Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians.
    Dhar GC
    Can Fam Physician; 2009 Aug; 55(8):803-4. PubMed ID: 19675265
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensive glucose control and cardiovascular disease in type 2 diabetes--should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials.
    Gaede P
    Pol Arch Med Wewn; 2008 Nov; 118(11):619-21. PubMed ID: 19140564
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes. Insights from the extended follow-up of the ACCORD trial.
    Zoungas S; Woodward M
    Nat Rev Cardiol; 2011 Jun; 8(6):308-10. PubMed ID: 21502962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough?
    Triplitt C
    Consult Pharm; 2010 Jun; 25 Suppl B():19-27. PubMed ID: 20726379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
    Mannucci E; Monami M; Ceriello A; Rotella CM
    Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hypoglycemia and cardiovascular risk].
    Avogaro A
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients.
    Karalliedde J; Gnudi L
    Nephrol Dial Transplant; 2008 Jun; 23(6):1796-8. PubMed ID: 18403430
    [No Abstract]   [Full Text] [Related]  

  • 9. Intensified glucose control in type 2 diabetes--whose agenda?
    Yudkin JS; Richter B; Gale EA
    Lancet; 2011 Apr; 377(9773):1220-2. PubMed ID: 21093903
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetes specialists keep ACCORD data in perspective.
    Traynor K
    Am J Health Syst Pharm; 2008 Mar; 65(6):488, 490. PubMed ID: 18319488
    [No Abstract]   [Full Text] [Related]  

  • 11. Type 2 diabetes and HbA1c targets.
    Prescrire Int; 2008 Dec; 17(98):254. PubMed ID: 19425272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].
    Füchtenbusch M; Hummel M
    MMW Fortschr Med; 2008 Apr; 150(17):42-4. PubMed ID: 18510157
    [No Abstract]   [Full Text] [Related]  

  • 13. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin glargine in the treatment of type 1 and type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2006; 2(1):59-67. PubMed ID: 17319470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes.
    Martin CL
    Diabetes Educ; 2007; 33 Suppl 1():6S-13S. PubMed ID: 17272803
    [No Abstract]   [Full Text] [Related]  

  • 16. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
    Lipska KJ; Krumholz HM
    JAMA; 2017 Mar; 317(10):1017-1018. PubMed ID: 28125758
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetes. Paradoxical effects of tightly controlled blood sugar.
    Taubes G
    Science; 2008 Oct; 322(5900):365-7. PubMed ID: 18927369
    [No Abstract]   [Full Text] [Related]  

  • 18. New Medications for the Treatment of Diabetes.
    Garg SK; Giordano D
    Diabetes Technol Ther; 2019 Feb; 21(S1):S160-S171. PubMed ID: 30785325
    [No Abstract]   [Full Text] [Related]  

  • 19. [Glycemic targets and cardiovascular morbi-mortality].
    Bordier L; Bauduceau B
    Presse Med; 2013 May; 42(5):855-60. PubMed ID: 23286961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes.
    Matthews DR; Tsapas A
    Diab Vasc Dis Res; 2008 Sep; 5(3):216-8. PubMed ID: 18777497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.